Brief: Egetis Gets Conditional FDA Name Acceptance
08/04/2026 12:21
April 8 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: RECEIVES CONDITIONAL FDA ACCEPTANCE OF PROPRIETARY NAME EMCITATE FINAL APPROVAL OF EMCITATE NAME RESERVED UNTIL NDA APPROVAL APPLICATION GRANTED PRIORITY REVIEW WITH PDUFA DATE OF SEPTEMBER 28, 2026 Source text: ID:nMFN1Xh7mf Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))